Form 4 · BMY
Bristol Myers Squibb CEO Christopher S. Boerner reports exercising or converting 2,964 shares
Part of a grouped insider digest: see all related filings with totals →
Christopher S. Boerner, Bristol Myers Squibb's Chief Executive Officer and a director, filed a Form 4 on Nov 3, 2026 at 4:30 PM ET reporting transactions on Nov 1, 2026.
The filing reports 2,964 shares in an exercise or conversion of a derivative security (code M); 1,724 shares withheld to pay the exercise price or tax (code F); and 406 shares in an other acquisition or disposition (code J).
After these transactions, the filing lists 23,097 shares of Common Stock, $0.10 par value held directly.
Effect on holdings
Taken together, the rows reported here raised Christopher S. Boerner's directly held shares by 7.7%, from 21,451 to 23,097.
Reporting person
- Christopher S. Boerner, Chief Executive Officer and a director (as filed: BOERNER CHRISTOPHER S.)
Transactions as reported
| Date | Code | Security | Shares | Price | Acquired or disposed | Held after | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-11-01 | M | Common Stock, $0.10 par value | 2,964 | Acquired | 24,415 | Direct | |
| 2026-11-01 | J | Common Stock, $0.10 par value | 406 | Acquired | 24,821 | Direct | |
| 2026-11-01 | F | Common Stock, $0.10 par value | 1,724 | $62.48 | Disposed | 23,097 | Direct |
| 2026-11-01 | M | Market Share Units (derivative) | 2,964 | Disposed | 2,966 | Direct |
Codes: P purchase, S sale, A grant or award, M/X/C exercise or conversion, F shares withheld for taxes or the exercise price, G gift. Prices are as reported; some are weighted averages of several trades.
Source
- Form 4 filed Nov 3, 2026 (document)
- Filing index on SEC EDGAR (all documents and exhibits)
Bristol Myers Squibb company file → · More Bristol Myers Squibb filings
Disclosures
- Editor holdings in BMY
- The editor holds no position in Bristol Myers Squibb (BMY). As of Nov 11, 2026.
- Last updated
- Nov 3, 2026
A summary of a public filing for general education, the same for every reader. Not a recommendation to buy, sell or hold BMY.